Susannah Gray - 23 Sep 2026 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Reporting relationship: Director
Issuer ticker: TBPH
Reported as of: 23 Sep 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Sep 2026, 20:31:25 UTC
Prior SEC filing: 18 Jun 2026
Source filing: View source filing
Reporting owner signature: /s/ Brett A. Grimaud, Attorney-in-Fact

Key filing fact

Susannah Gray filed Form 4 for Theravance Biopharma, Inc. (TBPH) on 24 Sep 2026.

Key facts

This page summarizes Susannah Gray's Form 4 filing for Theravance Biopharma, Inc. (TBPH).
7 reported transactions and 5 derivative rows are listed below.
Accepted by SEC: 24 Sep 2026, 20:31.

Change

Previous filing in this sequence was filed on 18 Jun 2026.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001833453 Primary reporting owner

GRAY SUSANNAH

Relationship: Director
Address: C/O THERAVANCE BIOPHARMA US, LLC, 901 GATEWAY BLVD, SOUTH SAN FRANCISCO
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Signature date: 24 Sep 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TBPH transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -42,137
Change %: -88%
Price
Shares after: 6,009
Date: 23 Sep 2026
Ownership: Direct
Footnotes: F1

TBPH transaction

Ordinary Shares

Disposed to Issuer

Transaction value
Shares: -6,009
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Footnotes: F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TBPH transaction Derivative

Share Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -32,666
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 32,666
Exercise price: $9.87
Footnotes: F3

TBPH transaction Derivative

Share Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -22,044
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 22,044
Exercise price: $10.95
Footnotes: F3

TBPH transaction Derivative

Share Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -23,576
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 23,576
Exercise price: $9.49
Footnotes: F3

TBPH transaction Derivative

Share Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -24,258
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 24,258
Exercise price: $9.39
Footnotes: F3

TBPH transaction Derivative

Share Option (Right to Buy)

Disposed to Issuer

Transaction value
Shares: -13,398
Change %: -100%
Price
Shares after: 0
Date: 23 Sep 2026
Ownership: Direct
Underlying class: Ordinary Shares
Underlying amount: 13,398
Exercise price: $16.64
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Susannah Gray is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 3 footnotes

Footnote F1

On September 23, 2026, pursuant to that certain Agreement and Plan of Merger (the "Merger Agreement"), dated June 28, 2026, by and among the Issuer, Zymeworks Inc. ("Parent"), and Zymeworks Merger Sub 1, a wholly owned subsidiary of Parent, the Issuer became a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger (the "Effective Time"), pursuant to the Merger Agreement, each ordinary share, par value $0.00001 per share, of the Issuer ("Ordinary Share") held by the reporting person as of immediately prior to the Effective Time was cancelled and converted into the right to receive (i) $17.00 in cash, without interest (the "Per Share Cash Consideration") and (ii) one contingent value right (a "CVR"). Each CVR represents a non-tradeable contractual contingent right to receive cash payments based on the achievement of certain commercial milestones following the Effective Time.

Footnote F2

At the Effective Time, pursuant to the Merger Agreement, each award of restricted stock units of the Issuer (a "Company RSU Award") that was outstanding as of immediately prior to the Effective Time was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the Per Share Cash Consideration multiplied by (ii) the number of Ordinary Shares underlying such Company RSU Award (subject to any required tax withholdings as provided in the Merger Agreement) plus (iii) one CVR for each Ordinary Share underlying such Company RSU Award.

Footnote F3

At the Effective Time, each option to purchase Ordinary Shares outstanding and unexercised as of immediately prior to the Effective Time, whether vested or unvested (a "Company Option"), was cancelled and converted into the right to receive an amount in cash, without interest, equal to (i) the excess, if any, of the Per Share Cash Consideration over the exercise price of such Company Option, multiplied by (ii) the number of Ordinary Shares underlying such Company Option plus (iii) one CVR for each Ordinary Share underlying such Company Option.